Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas

EMBO Molecular Medicine

Volumn 5, Issue 10, 2013, Pages 1537-1555

  Li, Junwei ^a   Bonifati, Serena ^a   Hristov, Georgi ^a   Marttila, Tiina ^a   Valmary Degano, Séverine ^b   Stanzel, Sven ^a   Schnölzer, Martina ^a   Mougin, Christiane ^c   Aprahamian, Marc ^d   Grekova, Svitlana P ^a   Raykov, Zahari ^a   Rommelaere, Jean ^a   Marchini, Antonio ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^c HÔPITAL SAINT JACQUES   (France)

^d IRCAD   (France)

Author keywords

H 1PV; Pancreatic ductal adenocarcinomas; Parvovirus NS1 protein; Valproic acid; Viral oncotherapy

Indexed keywords

NONSTRUCTURAL PROTEIN 1; ONCOLYTIC PARVOVIRUS; VALPROIC ACID;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER REGRESSION; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; FEMALE; H-1 PARVOVIRUS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; OXIDATIVE STRESS; PANCREAS CARCINOMA; PRIORITY JOURNAL; RAT; TUMOR XENOGRAFT; UTERINE CERVIX CARCINOMA;

H-1PV; PANCREATIC DUCTAL ADENOCARCINOMAS; PARVOVIRUS NS1 PROTEIN; VALPROIC ACID; VIRAL ONCOTHERAPY;

ANIMALS; APOPTOSIS; CARCINOMA; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HELA CELLS; HISTONE DEACETYLASE INHIBITORS; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; ONCOLYTIC VIRUSES; OXIDATIVE STRESS; PANCREATIC NEOPLASMS; PARVOVIRUS; RATS; RATS, NUDE; UTERINE CERVICAL NEOPLASMS; VALPROIC ACID;

EID: 84884950651     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.1002/emmm.201302796     Document Type: Article

References (45)

1. Allaume X, El-Andaloussi N, Leuchs B, Bonifati S, Kulkarni A, Marttila T, Kaufmann JK, Nettelbeck DM, Kleinschmidt J, Rommelaere J, et al (2012) Retargeting of rat parvovirus H-1PV to cancer cells through genetic engineering of the viral capsid. J Virol 86: 3452-3465
2. Alvarez-Breckenridge CA, Yu J, Price R, Wei M, Wang Y, Nowicki MO, Ha YP, Bergin S, Hwang C, Fernandez SA, et al (2012) The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5/T-BET signaling and generation of gamma interferon. J Virol 86: 4566-4577
3. American Cancer Society (2012) Cancer Facts & Figures 2012. American Cancer Society, Atlanta, Georgia, USA
4. Armstrong JS, Whiteman M (2007) Measurement of reactive oxygen species in cells and mitochondria. Methods Cell Biol 80: 355-377
5. Atmaca A, Al-Batran SE, Maurer A, Neumann A, Heinzel T, Hentsch B, Schwarz SE, Hovelmann S, Gottlicher M, Knuth A, et al (2007) Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer 97: 177-182
6. Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bhola NE, Sanders ME, Granja-Ingram NM, Smith JJ, Meszoely IM, et al (2012) Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat Med 18: 1052-1059
7. Bodendorf U, Cziepluch C, Jauniaux JC, Rommelaere J, Salome N (1999) Nuclear export factor CRM1 interacts with nonstructural proteins NS2 from parvovirus minute virus of mice. J Virol 73: 7769-7779
8. Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, Nieva J, Hwang TH, Moon A, Patt R, et al (2011) Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477: 99-102
9. Caron C, Col E, Khochbin S (2003) The viral control of cellular acetylation signaling. Bioessays 25: 58-65
10. Castro F, Dirks WG, Fahnrich S, Hotz-Wagenblatt A, Pawlita M, Schmitt M (2013) High-throughput SNP-based authentication of human cell lines. Int J Cancer 132: 308-314
11. Coronel J, Cetina L, Pacheco I, Trejo-Becerril C, Gonzalez-Fierro A, de la Cruz-Hernandez E, Perez-Cardenas E, Taja-Chayeb L, Arias-Bofill D, Candelaria M et al (2010) A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results. Med Oncol 28 (Suppl 1): S540-S546
12. Cotmore SF, Christensen J, Nuesch JP, Tattersall P (1995) The NS1 polypeptide of the murine parvovirus minute virus of mice binds to DNA sequences containing the motif [ACCA]2-3. J Virol 69: 1652-1660
13. Dempe S, Stroh-Dege AY, Schwarz E, Rommelaere J, Dinsart C (2010) SMAD4: a predictive marker of PDAC cell permissiveness for oncolytic infection with parvovirus H-1PV. Int J Cancer 126: 2914-2927
14. El-Andaloussi N, Bonifati S, Kaufmann JK, Mailly L, Daeffler L, Deryckere F, Nettelbeck DM, Rommelaere J, Marchini A (2012) Generation of an adenovirus-parvovirus chimera with enhanced oncolytic potential. J Virol 86: 10418-10431
15. El-Andaloussi N, Endele M, Leuchs B, Bonifati S, Kleinschmidt J, Rommelaere J, Marchini A (2011) Novel adenovirus-based helper system to support production of recombinant parvovirus. Cancer Gene Ther 18: 240-249
16. Geletneky K, Huesing J, Rommelaere J, Schlehofer JR, Leuchs B, Dahm M, Krebs O, von Knebel Doeberitz M, Huber B, Hajda J (2012) Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol. BMC Cancer 12: 99
17. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG et al (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20: 6969-6978
18. Hristov G, Kramer M, Li J, El-Andaloussi N, Mora R, Daeffler L, Zentgraf H, Rommelaere J, Marchini A (2010) Through its nonstructural protein NS1, parvovirus H-1 induces apoptosis via accumulation of reactive oxygen species. J Virol 84: 5909-5922
19. Iseki H, Shimizukawa R, Sugiyama F, Kunita S, Iwama A, Onodera M, Nakauchi H, Yagami K (2005) Parvovirus nonstructural proteins induce an epigenetic modification through histone acetylation in host genes and revert tumor malignancy to benignancy. J Virol 79: 8886-8893
20. Johnstone RW (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1: 287-299
21. Katsura T, Iwai S, Ota Y, Shimizu H, Ikuta K, Yura Y (2009) The effects of trichostatin A on the oncolytic ability of herpes simplex virus for oral squamous cell carcinoma cells. Cancer Gene Ther 16: 237-245
22. Kestler J, Neeb B, Struyf S, Van Damme J, Cotmore SF, D'Abramo A, Tattersall P, Rommelaere J, Dinsart C, Cornelis JJ (1999) cis requirements for the efficient production of recombinant DNA vectors based on autonomous parvoviruses. Hum Gene Ther 10: 1619-1632
23. Kryston TB, Georgiev AB, Pissis P, Georgakilas AG (2011) Role of oxidative stress and DNA damage in human carcinogenesis. Mutat Res 711: 193-201
24. Lane AA, Chabner BA (2009) Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27: 5459-5468
25. Lee JH, Choy ML, Marks PA (2012) Mechanisms of resistance to histone deacetylase inhibitors. Adv Cancer Res 116: 39-86
26. Li J, Werner E, Hergenhahn M, Poirey R, Luo Z, Rommelaere J, Jauniaux JC (2005a) Expression profiling of human hepatoma cells reveals global repression of genes involved in cell proliferation, growth, and apoptosis upon infection with parvovirus H-1. J Virol 79: 2274-2286
27. Li XN, Shu Q, Su JM, Perlaky L, Blaney SM, Lau CC (2005b) Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. Mol Cancer Ther 4: 1912-1922
28. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408
29. Matthews GM, Newbold A, Johnstone RW (2012) Intrinsic and extrinsic apoptotic pathway signaling as determinants of histone deacetylase inhibitor antitumor activity. Adv Cancer Res 116: 165-197
30. Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38-51
31. Nguyen TL, Wilson MG, Hiscott J (2010) Oncolytic viruses and histone deacetylase inhibitors-a multi-pronged strategy to target tumor cells. Cytokine Growth Factor Rev 21: 153-159
32. Nuesch JP (2006) Regulation of the Non-Structural Protein Functions by Differential Synthesis, Modification and Trafficking, pp 275-289. Hodder Arnold E Ltd, London, United Kingdom
33. Nuesch JP, Lacroix J, Marchini A, Rommelaere J (2012) Molecular pathways: rodent parvoviruses-mechanisms of oncolysis and prospects for clinical cancer treatment. Clin Cancer Res 18: 3516-3523
34. Otsuki A, Patel A, Kasai K, Suzuki M, Kurozumi K, Chiocca EA, Saeki Y (2008) Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol Ther 16: 1546-1555
35. Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human studies revisited. FASEB J 22: 659-661
36. Robert C, Rassool FV (2012) HDAC inhibitors: roles of DNA damage and repair. Adv Cancer Res 116: 87-129
37. Rodriguez-Paredes M, Esteller M (2011) Cancer epigenetics reaches mainstream oncology. Nat Med 17: 330-339
38. Rommelaere J, Geletneky K, Angelova AL, Daeffler L, Dinsart C, Kiprianova I, Schlehofer JR, Raykov Z (2010) Oncolytic parvoviruses as cancer therapeutics. Cytokine Growth Factor Rev 21: 185-195
39. Russell SJ, Peng KW, Bell JC (2012) Oncolytic virotherapy. Nat Biotechnol 30: 658-670
40. Sandmann T, Jakobsen JS, Furlong EE (2006) ChIP-on-chip protocol for genome-wide analysis of transcription factor binding in Drosophila melanogaster embryos. Nat Protoc 1: 2839-2855
41. Spange S, Wagner T, Heinzel T, Kramer OH (2009) Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol 41: 185-198
42. Tang Y, Zhao W, Chen Y, Zhao Y, Gu W (2008) Acetylation is indispensable for p53 activation. Cell 133: 612-626
43. VanOosten RL, Earel, JK Jr, Griffith TS (2006) Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors. Cancer Gene Ther 13: 628-632
44. VanOosten RL, Earel, JK Jr, Griffith TS (2007) Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity. Apoptosis 12: 561-571
45. Verollet R (2008) A major step towards efficient sample preparation with bead-beating. Biotechniques 44: 832-833